Mission Therapeutics Ltd. landed £20 million (US$32 million) in second-round funding, evidence that some European investors still have a substantial appetite for preclinical biotechnology firms working in a cutting-edge area of science. Existing investors Sofinnova Partners, Imperial Innovations, S.R. One and Roche Venture Fund all followed their money, but the round also brought in another big pharma corporate venture arm, Pfizer Venture Investments.